Review
Published on 20 Nov 2024
Unveiling the fate and potential neuroprotective role of neural stem/progenitor cells in multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1438404
- 153 views
Type at least 3 characters
1,081 articles
Articles
Original Research
Accepted on 19 Nov 2024
Combining gene expression microarrays and Mendelian randomization: Exploring key immune-related genes in multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1437778
Original Research
Published on 19 Nov 2024
Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1486659
- 226 views
Systematic Review
Accepted on 18 Nov 2024
Comparative Efficacy and Tolerability of Ublituximab Versus other Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis of Randomized Trials
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1479476
Systematic Review
Accepted on 18 Nov 2024
The prevalence of obstructive sleep apnea-hypopnea syndrome in patients with multiple sclerosis: a systematic review and meta-analysis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1444470
Original Research
Published on 15 Nov 2024
Smartphone tests quantify lower extremities dysfunction in multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1408224
- 447 views
Original Research
Accepted on 14 Nov 2024
Integrative Multi-Omics Approach Using Random Forest and Artificial Neural Network Models for Early Diagnosis and Immune Infiltration Characterization in Ischemic Stroke
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1475582
Systematic Review
Accepted on 14 Nov 2024
Comparison of Different Exercise Modalities on Fatigue and Muscular Fitness in Patients with Multiple Sclerosis: A Systematic Review with Network, and Dose-Response Meta-Analyses
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1494368
Perspective
Accepted on 13 Nov 2024
Diagnostic Potential of Blood-based Biomarkers in Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1425046
Original Research
Published on 12 Nov 2024
Causal relationship between immune cells and Guillain-Barré syndrome: a Mendelian randomization study
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1446472
- 274 views
Original Research
Published on 06 Nov 2024
A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1475161
- 252 views
Case Report
Published on 30 Oct 2024
Case report: Primary cytomegalovirus infection in a patient with late onset multiple sclerosis treated with dimethyl fumarate
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1363876
- 498 views
Brief Research Report
Published on 30 Oct 2024
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1477335
- 445 views
Original Research
Published on 30 Oct 2024
Clinical characteristics and prognosis analysis of acute symptomatic seizures secondary to autoimmune encephalitis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1474888
- 332 views
Original Research
Accepted on 28 Oct 2024
MOGAD and NMOSD: insights on patients' radiological and laboratory findings from A single UAE center
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1480723
- 141 views
Original Research
Published on 24 Oct 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2024.1473284
- 613 views